IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

NCT ID: NCT02803580

Last Updated: 2019-09-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

209 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-17

Study Completion Date

2018-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged\>=40 years
2. Written informed consent to both participation in the study and privacy
3. Physician diagnosed IPF during the last 3 months based upon recent American Thoracic Society/European Resp. Society/Japanese Resp. Society/Latin American Thoracic Association guidelines 2011 (see Tables A1-A2 for High Resolution Chest Computer Tomography and histology criteria):

* Exclusion of other known causes of Interstitial Lung Disease (e.g. domestic and occupational environmental exposures, connective tissue disease and drug toxicity)
* Assessment of Idiopathic Pulmonary Fibrosis based on High Resolution Computed Tomography (HRCT) or HRCT and surgical lung biopsy if available.
4. Patient with further follow-up possible with enrolling investigator during planned study period
5. Patients capable of discernment and able to read or write in Italian language.

Exclusion Criteria

1. Inclusion in clinical trials or other IPF/ILD registries
2. Lung transplantation expected within the next 6 months
3. Pregnancy or breast feeding
Minimum Eligible Age

40 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

A.O.U. Policlinico Vittorio Emanuele

Catania, , Italy

Site Status

Osp. Clin. SS. Anunziata

Chieti, , Italy

Site Status

Ospedale Colonnello D Avanzo

Foggia, , Italy

Site Status

Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli

Forlì, , Italy

Site Status

Osp. S. Giuseppe Fatebenefratelli

Milan, , Italy

Site Status

Azienda Ospedaliera Policlinico di Modena

Modena, , Italy

Site Status

A.O. San Gerardo di Monza

Monza, , Italy

Site Status

Azienda Ospedaliera Universitaria "Federico II"

Napoli, , Italy

Site Status

Azienda Sanitaria Ospedale S. Luigi Gonzaga

Orbassano, , Italy

Site Status

Azienda Ospedaliera Universitaria di Padova

Padua, , Italy

Site Status

Fondazione IRCCS Policlinico S. Matteo

Pavia, , Italy

Site Status

Ospedale di Cisanello

Pisa, , Italy

Site Status

Pol. Universitario Tor Vergata

Roma, , Italy

Site Status

A.O. San Camillo Forlanini

Roma, , Italy

Site Status

Policlinico Gemelli

Roma, , Italy

Site Status

Policlinico Universitario di Sassari

Sassari, , Italy

Site Status

A.O.U. Senese Policlinico Santa Maria alle Scotte

Siena, , Italy

Site Status

Ospedale Riuniti di Ancona

Torrette-Ancona, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Poletti V, Vancheri C, Albera C, Harari S, Pesci A, Metella RR, Campolo B, Crespi G, Rizzoli S; FIBRONET study group. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. Respir Res. 2021 Feb 24;22(1):66. doi: 10.1186/s12931-021-01643-w.

Reference Type DERIVED
PMID: 33627105 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1199.262

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.